Pretax income is the income that a company earns before paying income taxes. Vaccinex's pretax income for the
three
months ended in Mar. 2024 was $-3.90 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.19 Mil.
Vaccinex's pretax margin was -3,747.12%.
During the past 8 years, Vaccinex's highest Pretax Margin was -2486.67%. The lowest was -57702.00%. And the median was -5252.35%.
Vaccinex Pre-Tax Income Historical Data
The historical data trend for Vaccinex's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vaccinex's Pre-Tax Income
For the Biotechnology subindustry, Vaccinex's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Vaccinex's Pre-Tax Income falls into.
Vaccinex Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Vaccinex's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex (NAS:VCNX) Pre-Tax Income Explanation
Vaccinex's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 8 years, Vaccinex's highest Pretax Margin was -2486.67%. The lowest was -57702.00%. And the median was -5252.35%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Vaccinex's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your 